# Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

> **NCT02007512** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 247 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** exemestane
- **DRUG:** Placebo (for enzalutamide)
- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT02007512
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-16
- **Primary completion:** 2016-09-23
- **Final completion:** 2024-08-23
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02007512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02007512, "Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02007512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*